Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2022 | DeFi: nirogacestat demonstrates improved PFS and ORR in progressing desmoid tumors

Tom Wei-Wu Chen, MD, National Taiwan University Hospital, Taipei, Taiwan, talk on The Phase III DeFi (NCT03785964) study of nirogacestat versus placebo for progressing desmoid tumors. The primary endpoint was progression-free survival (PFS) and secondary endpoints were safety, objective response rate (ORR), and patient-reported outcomes (PROs). The trial demonstrated statistically and clinically significant improvements in progression-free survival (PFS), objective response rates (ORR) and a manageable safety profile with nirogacestat versus placebo. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.